Terray Therapeutics, Inc. news

Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.

“We are incredibly fortunate to have Bassil join the Terray team,” said Jacob Berlin, Ph.D., Chief Executive Officer of Terray. “He is a true biotech pioneer who has shifted the paradigm in protein engineering. Hi

Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule therapeutics for diseases of aging, including cancer. 

Under the terms of the agreement, Ter

Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointment of Fiona Black, PhD to its Scientific Advisory Board, adding valuable expertise in interdisciplinary technology development of both market-leading, end-to-end product solutions and operationally efficient and scalable manufacturing processes.

“We are thrilled to welcome Dr. Black to our Scientific Advisory Board,” said Chief Executive Officer Jac

Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry. They join an expanding lineup of industry veterans including Vanessa Taylor, Terray’s Head of Biology and Preclinical Development, Narbe Mardirossian, Terray’s Head of Computational and Data Science and Craig Schulz, Terray’s Head of Automation. T

Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the closing of a $60 million Series A financing to advance its novel tNova platform and deliver therapies to patients faster than ever before. The financing was led by Madrona Venture Group with participation from a broad syndicate of new and existing investors, including Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Sahsen Ventures, Greentr